Search Result

Results for "

SARS-CoV-2-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (2) Angiotensin-converting Enzyme (ACE) (2) Apoptosis (1) Cathepsin (4) CDK (1) COX (1) Cyclin G-associated Kinase (GAK) (1) DNA/RNA Synthesis (3) Drug Derivative (2) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (2) ERK (2) HBV (2) HCV (2) IFNAR (2) Influenza Virus (1) Interleukin Related (5) Isotope-Labeled Compounds (4) JNK (1) Ligands for Target Protein for PROTAC (1) MAP3K (2) MEK (2) NF-κB (2) NOD-like Receptor (NLR) (2) p38 MAPK (2) Poly(ADP-ribose) Glycohydrolase (PARG) (3) PROTACs (1) Protease Activated Receptor (PAR) (3) Proteasome (1) Reference Standards (2) Reverse Transcriptase (2) SARS-CoV (86) Sec61 (2) Ser/Thr Protease (1) Sirtuin (1) TNF Receptor (3) TRP Channel (1) Virus Protease (11)
By Research Areas:	Cancer (6) Infection (87) Inflammation/Immunology (11) Metabolic Disease (3) Neurological Disease (2)
Click Chemistry:	Alkynes (3)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99340

Sotrovimab 4 Publications Verification VIR 7831; GSK-4182136	SARS-CoV	Infection Cancer
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .

HY-117626

LP-935509 1 Publications Verification	AAK1 Cyclin G-associated Kinase (GAK) SARS-CoV	Infection Neurological Disease Inflammation/Immunology
LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC₅₀ of 3.3 nM and a K_i of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC₅₀=14 nM) and a modest inhibitor of GAK (IC₅₀=320 nM). LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research .

HY-P99604

Cilgavimab AZD-1061; CoV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-113478S

Ursodeoxycholic acid-d4 Ursodeoxycholate-d₄; Ursodiol-d₄; UDCA-d₄	Isotope-Labeled Compounds	Infection Metabolic Disease
Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

HY-126085

(±)-Alliin 3 Publications Verification (±)-L-AlliIN	SARS-CoV	Infection
(±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of *SARS-CoV-2 (M_pro)* .

HY-145994

Obeldesivir 1 Publications Verification ATV006	SARS-CoV	Infection
Obeldesivir (ATV006) is a potent, orally active antiviral agent and ester proagents of GS-441524. Obeldesivir inhibits the replication of SARS-CoV-2 and its variants. Obeldesivir can be used for SARS-CoV-2 research .

HY-146248B

TFMU-ADPr diammonium	Poly(ADP-ribose) Glycohydrolase (PARG) SARS-CoV Protease Activated Receptor (PAR)	Metabolic Disease
TFMU-ADPr diammonium is a selective reporter substrate of SARS-CoV-2 Macro1 (IC₅₀=0.59 μM), with an excitation wavelength (λ_Ex) of 385 nm, and an emission wavelength (λ_Em) of 502 nm (or 495 nm). TFMU-ADPr diammonium can also undergo enzymatic hydrolysis with Poly(ADP-ribose) Glycohydrolase (PARG) sourced from human, Tetrahymena thermophila and ADP-ribosylhydrolase 3 from human to release fluorophores, thereby directly reporting total poly (ADP-ribose) hydrolase activity. TFMU-ADPr diammonium binds to the ADPr-binding site of SARS-CoV-2 Macro1, and its TFMU moiety inserts into the narrow hydrophobic groove of this protein. TFMU-ADPr diammonium can thus be used to evaluate small-molecule inhibitors targeting PAR hydrolases under in vitro conditions, to investigate the regulatory mechanisms of ADP-ribosyl catabolic enzymes, or to detect PAR hydrolase activity in whole-cell lysate assays. TFMU-ADPr diammonium is also applicable to COVID-19-related research .

HY-138113

Pyrrothiogatain 1 Publications Verification	DNA/RNA Synthesis Interleukin Related TNF Receptor Angiotensin-converting Enzyme (ACE) SARS-CoV	Infection Inflammation/Immunology Cancer
Pyrrothiogatain is a transcription factor GATA3 inhibitor with an IC₅₀ of 54.7 μM. Pyrrothiogatain inhibits the DNA-binding activity of GATA3 and inhibits the T helper 2 (Th2) cell differentiation and expression of Th2 cytokines. Pyrrothiogatain shows anti-infection effect by inhibiting ACE2 expression. Pyrrothiogatain can be used for the researches of inflammation, immunology, infection and cancer, such as colon cancer and SARS-CoV-2 infection .

HY-150784

XR8-89	SARS-CoV	Infection
XR8-89 is a potent papain-like protease (PL ^pro) inhibitor with an IC₅₀ value of 0.1 μM. XR8-89 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. XR8-89 can be used for SARS-CoV-2 research .

HY-131603

Lamivudine triphosphate 3TCTP	Reverse Transcriptase HCV HBV SARS-CoV Drug Derivative	Infection
Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .

HY-146248

TFMU-ADPr	SARS-CoV Poly(ADP-ribose) Glycohydrolase (PARG) Protease Activated Receptor (PAR)	Infection
TFMU-ADPr is a selective reporter substrate of SARS-CoV-2 Macro1 (IC₅₀=0.59 μM), with an excitation wavelength (λ_Ex) of 385 nm, and an emission wavelength (λ_Em) of 502 nm (or 495 nm). TFMU-ADPr can also undergo enzymatic hydrolysis with Poly(ADP-ribose) Glycohydrolase (PARG) sourced from human, Tetrahymena thermophila and ADP-ribosylhydrolase 3 from human to release fluorophores, thereby directly reporting total poly (ADP-ribose) hydrolase activity. TFMU-ADPr binds to the ADPr-binding site of SARS-CoV-2 Macro1, and its TFMU moiety inserts into the narrow hydrophobic groove of this protein. TFMU-ADPr can thus be used to evaluate small-molecule inhibitors targeting PAR hydrolases under in vitro conditions, to investigate the regulatory mechanisms of ADP-ribosyl catabolic enzymes, or to detect PAR hydrolase activity in whole-cell lysate assays. TFMU-ADPr is also applicable to COVID-19-related research .

HY-W196368

Thymohydroquinone	COX SARS-CoV	Infection Inflammation/Immunology Cancer
Thymohydroquinone is a COX-2 inhibitor and anti-SARS-CoV-2 agent that induces cytotoxicity, antiproliferative effects and inhibits tumor growth. Thymohydroquinone cannot scavenge superoxide radicals via σ (hydrogen atom transfer) and π-π attacks with superoxide anions. Thymohydroquinone can be used in research related to squamous cell carcinoma, fibrosarcoma and coronavirus disease 2019 (SARS-CoV-2* infection)* .

HY-N3389

Licoisoflavone A 2 Publications Verification	SARS-CoV Sirtuin CDK Apoptosis	Infection Metabolic Disease Cancer
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and *SARS-CoV-2* infection .

HY-135860

*SARS-CoV-2-IN-1*	Virus Protease SARS-CoV	Infection
SARS-CoV-2-IN-1 is a potent Mpro inhibitor. SARS-CoV-2-IN-1 inhibits the purified recombinant SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with IC₅₀s of 0.67, 0.90 and 0.58 μM, respectively .

HY-155488

SHEN26 ATV014	SARS-CoV	Infection
SHEN26 (ATY014) is a potent and orally active RdRp inhibitor, with an IC₅₀ for *SARS-CoV-2* is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 (HY-103586). SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for the research of coronavirus disease 2019 (COVID-19) .

HY-P5522A

TriDAP dihydrochloride 1 Publications Verification L-Ala-γ-D-Glu-meso-diamINopimelic acid dihydrochloride	NOD-like Receptor (NLR) NF-κB MAP3K MEK ERK p38 MAPK Interleukin Related SARS-CoV	Infection Inflammation/Immunology
TriDAP dihydrochloride (L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride) is a NOD1 agonist with a K_d value of 34.5 μM. TriDAP dihydrochloride enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP dihydrochloride downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP dihydrochloride decreases IκBα levels and increases p65 levels. TriDAP dihydrochloride induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP dihydrochloride increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP dihydrochloride can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and *SARS-CoV-2* infection .

HY-153533A

GRL-1720 TFA	SARS-CoV	Infection
GRL-1720 TFA is a potent inhibitor of SARS-CoV-2 Mpro with an EC50 value of 15 μM. GRL-1720 TFA shows anti-SARS-CoV2 activity .

HY-155813

MPI60	SARS-CoV	Infection
MPI60 is a potent SARS-CoV-2 M ^Pro inhibitor with high antiviral potency, low cellular cytotoxicity, and high in vitro metabolic stability. MPI60 can be used for SARS-CoV-2 research .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-124304

Pinokalant LOE-908	TRP Channel SARS-CoV	Neurological Disease
Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity .

HY-162484

GZNL-P36	SARS-CoV Virus Protease	Infection
GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PL ^pro), with an IC₅₀ of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC₅₀ range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration C_max of 549 ng/mL, a half-life T_1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse .

HY-139165

AT-9010	SARS-CoV	Infection
AT-9010, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 can inhibit *SARS-CoV-2* replication .

HY-139165A

AT-9010 tetrasodium 1 Publications Verification	SARS-CoV	Infection
AT-9010 tetrasodium, a triphosphate active metabolite of AT-527, is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 tetrasodium can inhibit *SARS-CoV-2* replication .

HY-P9801

Anti-Spike-RBD mAb 1 Publications Verification SARS-CoV-2 (2019-nCoV) Spike RBD Antibody	SARS-CoV	Infection
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .

HY-179088

AVI-6451	SARS-CoV	Infection
AVI-6451 is a novel orally effective *SARS-CoV-2* Mac1 (IC₅₀ = 28 nM) inhibitor. AVI-6451 can reduce viral load. AVI-6451 can be used for research on viral infections .

HY-146248A

TFMU-ADPr triethylamine	Poly(ADP-ribose) Glycohydrolase (PARG) SARS-CoV Protease Activated Receptor (PAR)	Others
TFMU-ADPr triethylamine is a selective reporter substrate of SARS-CoV-2 Macro1 (IC₅₀=0.59 μM), with an excitation wavelength (λ_Ex) of 385 nm, and an emission wavelength (λ_Em) of 502 nm (or 495 nm). TFMU-ADPr triethylamine can also undergo enzymatic hydrolysis with Poly(ADP-ribose) Glycohydrolase (PARG) sourced from human, Tetrahymena thermophila and ADP-ribosylhydrolase 3 from human to release fluorophores, thereby directly reporting total poly (ADP-ribose) hydrolase activity. TFMU-ADPr triethylamine binds to the ADPr-binding site of SARS-CoV-2 Macro1, and its TFMU moiety inserts into the narrow hydrophobic groove of this protein. TFMU-ADPr triethylamine can thus be used to evaluate small-molecule inhibitors targeting PAR hydrolases under in vitro conditions, to investigate the regulatory mechanisms of ADP-ribosyl catabolic enzymes, or to detect PAR hydrolase activity in whole-cell lysate assays. TFMU-ADPr triethylamine is also applicable to COVID-19-related research .

HY-P11012

EK1	SARS-CoV	Infection
EK1 is a peptide-based fusion inhibitor of coronaviruses (CoVs) with broad spectrum inhibition to a number of CoV species. EK1 shows substantially improved pan-CoV fusion inhibitory activity. EK1 potently inhibits SARS-CoV-2. EK1 can form a stable six-helix bundle (6HB) structure with both short α-hCoV and long β-hCoV N-terminal heptad repeats .

HY-P5522

TriDAP L-Ala-γ-D-Glu-meso-diamINopimelic acid	NOD-like Receptor (NLR) NF-κB MAP3K MEK ERK p38 MAPK Interleukin Related SARS-CoV	Infection Inflammation/Immunology
TriDAP (L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a NOD1 agonist with a K_d value of 34.5 μM. TriDAP enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP decreases IκBα levels and increases p65 levels. TriDAP induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and *SARS-CoV-2* infection .

HY-157477

SARS-CoV-2 3CLpro-IN-22	SARS-CoV Cathepsin	Infection
SARS-CoV-2 3CLpro-IN-22 (Compound 17) is a cathepsin L (CTSL ) inhibitor with an IC₅₀ value of 32.5 nM. SARS-CoV-2 3CLpro-IN-22 can be used for the study of SARS-CoV-2 virus .

HY-P5168S

GPSVFPLAPSSK-13C6,15N2	Isotope-Labeled Compounds SARS-CoV	Infection
GPSVFPLAPSSK- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .

HY-175461

AVI-4206	SARS-CoV	Infection
AVI-4206 is a selective Mac1 inhibitor with an lC₅₀ of 64 nM. AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit in an animal model of SARS-CoV-2 infection. AVI-4206 can be used the study of *SARS-CoV-2* infection .

HY-169171

Cathepsin L-IN-5	Cathepsin	Infection
Cathepsin L-IN-5 (D6-3) is a potent Cathepsin L (CatL) inhibitor with an IC₅₀ of 0.27 nM. Cathepsin L-IN-5 effectively blocks the CatL function and substantially hinders the entry of the SARS-CoV-2 pseudovirus to cells by inhibiting the cleavage of the spike protein. Cathepsin L-IN-5 can be utilized in SARS-CoV-2 research .

HY-163029

CTSL/B-IN-1	Cathepsin SARS-CoV	Infection
CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC₅₀s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research .

HY-173148

TKB272	SARS-CoV	Infection
TKB272 is an orally active and selective antiviral agent targeting the main protease (Mpro) of SARS-CoV-2. It effectively blocks the infection and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC₅₀ of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC₅₀ as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC₅₀ of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg(K18-hACE2)2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection .

HY-131603B

Lamivudine triphosphate TEA 3TCTP TEA	Reverse Transcriptase HCV HBV SARS-CoV Drug Derivative	Infection
Lamivudine triphosphate (3TCTP) TEA is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate TEA inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate TEA is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate TEA can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .

HY-150062

SARS-CoV-2 nsp3-IN-1	SARS-CoV	Infection
SARS-CoV-2 nsp3-IN-1 (Compound 15c) is a Mac1 (SARS-CoV-2 nsp3 macrodomain) inhibitor with the IC₅₀ value of 6.1 μM. SARS-CoV-2 nsp3-IN-1 can inhibit Mac1 ADP-ribosylhydrolase activity. SARS-CoV-2 nsp3-IN-1 demonstrates notable selectivity for coronavirus macrodomains, especially towards SARS-CoV-2 Mac1 .

HY-175344

TMP1	SARS-CoV Virus Protease Ser/Thr Protease	Infection Inflammation/Immunology
TMP1 is an orally active bispecific inhibitor of M pro (IC₅₀ = 312.5 nM)/TMPRSS2 (IC₅₀ = 1.28 μM, K_D = 10.10 μM). TMP1 exhibits broad protection against different SARS-CoV-2 variants in vitro. TMP1 cross-protects against highly pathogenic coronaviruses (SARS-CoV-1, SARS-CoV-2, and MERS-CoV) in vivo and effectively blocks the transmission of *SARS-CoV-2*. TMP1 can inhibit infection by SARS-CoV-2 escape mutants that are resistant to Nivolumab (HY-P9903). TMP1 can be used in coronavirus research .

HY-161114

MDOLL-0229	SARS-CoV	Infection
MDOLL-0229 (compound 27) is an antiviral agent that targets SARS-CoV-2 Mac1 and repress coronavirus replication. MDOLL-0229 inhibits SARS-CoV-2 Mac1 with an IC₅₀ of 2.1 µM .

HY-151113

ZINC000104379474	SARS-CoV	Infection
ZINC000104379474 is a compound that targets *SARS-CoV-2 endoribonuclease* .

HY-N10604

Dihydromaniwamycin E	Influenza Virus SARS-CoV	Infection
Dihydromaniwamycin E is a heat-shock metabolite with antiviral activity against influenza and *SARS-CoV-2* viruses .

HY-173134

SARS-CoV-2 RdRp-IN-1	SARS-CoV	Infection
SARS-CoV-2 RdRp-IN-1 (Compound PAP-2) is a potent SARS-CoV-2 RdRp inhibitor, with an EC₅₀ of 1.11 μM. SARS-CoV-2 RdRp-IN-1 can bind directly to SARS-CoV-2 RdRp, fully resistance to the exoribonuclease (ExoN) and exhibit broad spectrum anti-CoV activities .

HY-169200

SARS-CoV-2 Mpro-IN-26	SARS-CoV	Cancer
SARS-CoV-2 Mpro-IN-26 (compund 13) is a covalent inhibitor of *SARS-CoV-2 Mpro* .

HY-155057

SARS-CoV-2 Mpro-IN-8	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-8 (compound 6b) is an antiviral agent with anti-SARS-CoV-2* properties .*

HY-163912

JZD-07	SARS-CoV	Infection
JZD-07 is a potent SARS-CoV 3CLpro inhibitor. JZD-07 can be used in the study of *SARS-CoV-2* infection .

HY-160943A

F594-1001 hydrochloride	SARS-CoV	Infection
F594-1001 (compound 6) hydrochloride is a potent and highly selective *SARS-CoV-2 Mac1-ADP-ribose* inhibitor with IC₅₀s of 8.5 μM, 68 μM and 45 μM for SARS-CoV-2 in AS, FP, and FRET assays, respectively. F594-1001 hydrochloride directly binds to SARS-CoV-2 Mac1 and exhibits a dose-dependent inhibition of Mac1 ADP-ribosylhydrolase activity .

HY-160943

F594-1001	SARS-CoV	Infection
F594-1001 (compound 6) is a potent and highly selective *SARS-CoV-2 Mac1-ADP-ribose* inhibitor with IC₅₀s of 8.5 μM, 68 μM and 45 μM for SARS-CoV-2 in AS, FP, and FRET assays, respectively. F594-1001 directly binds to SARS-CoV-2 Mac1 and exhibits a dose-dependent inhibition of Mac1 ADP-ribosylhydrolase activity .

HY-162598

CET-1	SARS-CoV	Infection
CET-1 is an antiviral agent that inhibits *SARS-CoV-2*. CET-1 significantly prevents pseudovirus from entering ACE2 ^h cells .

HY-158905

MTDB-Alkyne MTDB-Alk	SARS-CoV	Infection
MTDB-Alkyne is an alkyne-containing click chemistry reagent. MTDB-Alkyne can be used to synthesize Proximity-Induced Nucleic Acid Degrader (PINAD) for the degradation of SARS-CoV-2 RNA .

HY-153533

GRL-1720	SARS-CoV	Infection
GRL-1720 is a potent SARS-CoV-2 Mpro inhibitor with an EC₅₀ value of 15 µM. GRL-1720 shows anti-SARS-CoV2 activity .

HY-126085R

(±)-Alliin (Standard) (±)-L-AlliIN (Standard)	Reference Standards SARS-CoV	Infection
(±)-Alliin (Standard) is the analytical standard of (±)-Alliin. This product is intended for research and analytical applications. (±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of SARS-CoV-2 (Mpro) .

Cat. No.	Product Name	Type

HY-146248

TFMU-ADPr

Fluorescent Dyes

TFMU-ADPr is a selective reporter substrate of SARS-CoV-2 Macro1 (IC₅₀=0.59 μM), with an excitation wavelength (λ_Ex) of 385 nm, and an emission wavelength (λ_Em) of 502 nm (or 495 nm). TFMU-ADPr can also undergo enzymatic hydrolysis with Poly(ADP-ribose) Glycohydrolase (PARG) sourced from human, Tetrahymena thermophila and ADP-ribosylhydrolase 3 from human to release fluorophores, thereby directly reporting total poly (ADP-ribose) hydrolase activity. TFMU-ADPr binds to the ADPr-binding site of SARS-CoV-2 Macro1, and its TFMU moiety inserts into the narrow hydrophobic groove of this protein. TFMU-ADPr can thus be used to evaluate small-molecule inhibitors targeting PAR hydrolases under in vitro conditions, to investigate the regulatory mechanisms of ADP-ribosyl catabolic enzymes, or to detect PAR hydrolase activity in whole-cell lysate assays. TFMU-ADPr is also applicable to COVID-19-related research .

Cat. No.	Product Name	Target	Research Area

HY-P5522A

TriDAP dihydrochloride 1 Publications Verification L-Ala-γ-D-Glu-meso-diamINopimelic acid dihydrochloride	NOD-like Receptor (NLR) NF-κB MAP3K MEK ERK p38 MAPK Interleukin Related SARS-CoV	Infection Inflammation/Immunology
TriDAP dihydrochloride (L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride) is a NOD1 agonist with a K_d value of 34.5 μM. TriDAP dihydrochloride enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP dihydrochloride downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP dihydrochloride decreases IκBα levels and increases p65 levels. TriDAP dihydrochloride induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP dihydrochloride increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP dihydrochloride can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and *SARS-CoV-2* infection .

HY-P11012

EK1	SARS-CoV	Infection
EK1 is a peptide-based fusion inhibitor of coronaviruses (CoVs) with broad spectrum inhibition to a number of CoV species. EK1 shows substantially improved pan-CoV fusion inhibitory activity. EK1 potently inhibits SARS-CoV-2. EK1 can form a stable six-helix bundle (6HB) structure with both short α-hCoV and long β-hCoV N-terminal heptad repeats .

HY-P5522

TriDAP L-Ala-γ-D-Glu-meso-diamINopimelic acid	NOD-like Receptor (NLR) NF-κB MAP3K MEK ERK p38 MAPK Interleukin Related SARS-CoV	Infection Inflammation/Immunology
TriDAP (L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a NOD1 agonist with a K_d value of 34.5 μM. TriDAP enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP decreases IκBα levels and increases p65 levels. TriDAP induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and *SARS-CoV-2* infection .

HY-P5168S

GPSVFPLAPSSK-13C6,15N2	Isotope-Labeled Compounds SARS-CoV	Infection
GPSVFPLAPSSK- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .

HY-P5168AS

GPSVFPLAPSSK-13C6,15N2 TFA	Isotope-Labeled Compounds SARS-CoV	Infection
GPSVFPLAPSSK- ¹³C₆, ¹⁵N₂ TFA is the ¹³C- and ¹⁵N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .

HY-P11464

SARS-CoV-2 Spike receptor binding domain, RBD (371-394)	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
SARS-CoV-2 Spike receptor binding domain, RBD (371-394) is a peptide from SARS-CoV-2 spike receptor-binding domain. SARS-CoV-2 spike protein receptor-binding domain binds to ACE2. SARS-CoV-2 Spike receptor binding domain, RBD (371-394) can be used in the research of SARS-CoV-2 infection .

HY-P10466A

KZR-8445 TFA	Sec61 SARS-CoV Interleukin Related TNF Receptor IFNAR	Infection Inflammation/Immunology
KZR-8445 TFA, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 TFA binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 TFA inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 TFA inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 TFA blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 TFA can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection .

HY-P10466

KZR-8445	Sec61 SARS-CoV Interleukin Related TNF Receptor IFNAR	Infection Inflammation/Immunology
KZR-8445, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99340

Sotrovimab 4 Publications Verification VIR 7831; GSK-4182136	SARS-CoV	Infection Cancer
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .

HY-P99604

Cilgavimab AZD-1061; CoV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-P9801

Anti-Spike-RBD mAb 1 Publications Verification SARS-CoV-2 (2019-nCoV) Spike RBD Antibody	SARS-CoV	Infection
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .

HY-P990816

*Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29)*	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) reacts with the N-terminal domain (NTD) in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) can be used for the detections of flow cytometry and ELISA in SARS-CoV-2 infection .

HY-P990815

*Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)*	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection .

HY-P990814

*Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)*	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection .

HY-P992281

Anti-Nucleocapsid Antibody (N-18)	SARS-CoV	Infection
Anti-Nucleocapsid Antibody (N-18) is an antibody targeting Nucleocapsid, a structural protein of coronaviruses. Anti-Nucleocapsid Antibody (N-18) is applicable to studies on SARS-CoV-2 infection .

HY-P992282

Anti-Nucleocapsid Antibody (N-P10)	SARS-CoV	Infection
Anti-Nucleocapsid Antibody (N-P10) is a highly specific SARS-CoV-2 Nucleocapsid (N) protein-targeted recombinant monoclonal antibody. Anti-Nucleocapsid Antibody (N-P10) can be used for research on SARS-CoV-2 infection .

HY-P992283

Anti-Nucleocapsid Antibody (N-P11)	SARS-CoV	Infection
Anti-Nucleocapsid Antibody (N-P11) is a highly specific SARS-CoV-2 Nucleocapsid (N) protein-targeted recombinant monoclonal antibody. Anti-Nucleocapsid Antibody (N-P11) can be used for research on SARS-CoV-2 infection .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-126085

(±)-Alliin 3 Publications Verification (±)-L-AlliIN	Infection Liliaceae Classification of Application Fields Ketones, Aldehydes, Acids Plants Disease Research Fields A．Sativam L. var．Viviparum Regel Source Classification	SARS-CoV
(±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of *SARS-CoV-2 (M_pro)* .

HY-W196368

Thymohydroquinone	Structural Classification Nigella sativa L. Ranunculaceae Phenols Polyphenols Plants Source Classification	COX SARS-CoV
Thymohydroquinone is a COX-2 inhibitor and anti-SARS-CoV-2 agent that induces cytotoxicity, antiproliferative effects and inhibits tumor growth. Thymohydroquinone cannot scavenge superoxide radicals via σ (hydrogen atom transfer) and π-π attacks with superoxide anions. Thymohydroquinone can be used in research related to squamous cell carcinoma, fibrosarcoma and coronavirus disease 2019 (SARS-CoV-2* infection)* .

HY-N3389

Licoisoflavone A 2 Publications Verification	Flavonoids Classification of Application Fields Leguminosae Phenols Polyphenols Metabolic Disease Plants Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones Source Classification	SARS-CoV Sirtuin CDK Apoptosis
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and *SARS-CoV-2* infection .

HY-N10604

Dihydromaniwamycin E	Natural Products Microorganisms	Influenza Virus SARS-CoV
Dihydromaniwamycin E is a heat-shock metabolite with antiviral activity against influenza and *SARS-CoV-2* viruses .

HY-126085R

(±)-Alliin (Standard) (±)-L-AlliIN (Standard)	Liliaceae Ketones, Aldehydes, Acids Plants A．Sativam L. var．Viviparum Regel Source Classification	Reference Standards SARS-CoV
(±)-Alliin (Standard) is the analytical standard of (±)-Alliin. This product is intended for research and analytical applications. (±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of SARS-CoV-2 (Mpro) .

HY-134222AR

N-Acetylserine (Standard) N-Acetyl-L-serINe (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
N-Acetylserine (Standard) is the analytical standard of N-Acetylserine (HY-134222A). This product is intended for research and analytical applications. N-Acetylserine (N-Acetyl-L-serine) is a physiological inducer of cysteine biosynthesis and activator of CysB. N-Acetylserine can bind to the CysB apoprotein. N-Acetylserine stimulates cysJIH transcription in vitro. N-Acetylserine can be used in the research of SARS-CoV-2 infection .

Cat. No.	Product Name	Chemical Structure

HY-113478S

Ursodeoxycholic acid-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

HY-P5168S

GPSVFPLAPSSK-13C6,15N2
GPSVFPLAPSSK- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .

HY-P5168AS

GPSVFPLAPSSK-13C6,15N2 TFA
GPSVFPLAPSSK- ¹³C₆, ¹⁵N₂ TFA is the ¹³C- and ¹⁵N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .

HY-134222AS

N-Acetylserine-d3
N-Acetylserine-d₃ is the deuterium labeled N-Acetylserine (HY-134222A). N-Acetylserine (N-Acetyl-L-serine) is a physiological inducer of cysteine biosynthesis and activator of CysB. N-Acetylserine can bind to the CysB apoprotein. N-Acetylserine stimulates cysJIH transcription in vitro. N-Acetylserine can be used in the research of SARS-CoV-2 infection .

Cat. No.	Product Name		Classification

HY-158905

MTDB-Alkyne MTDB-Alk		Alkynes
MTDB-Alkyne is an alkyne-containing click chemistry reagent. MTDB-Alkyne can be used to synthesize Proximity-Induced Nucleic Acid Degrader (PINAD) for the degradation of SARS-CoV-2 RNA .

HY-162507

2'-RIBOTAC-U recruiter-linker		Alkynes
2'-RIBOTAC-U recruiter-linker (Compound 9) consists of RNase L recruiter and linker. 2'-RIBOTAC-U recruiter-linker is reacted separately with 2’-azido-uridine or 5’-azidomethyl-uridine via copper-catalyzed click chemistry, resulting in the formation of 2’-RIBOTAC-U and 5’-RIBOTAC-U, respectively. 2’-RIBOTAC-U has *anti-SARS-CoV-2* activity .

HY-181033

(M)-AVI-4773		Alkynes
(M)-AVI-4773 is an orally active, blood-brain barrier permeable coronaviruses M ^Pro inhibitor with an IC₅₀ of 2.5 nM aginst SARS-CoV-2 M ^Pro. (M)-AVI-4773 produces a rapid onset antiviral effect in mouse models of MERS-CoV and SARS-CoV-2 infection .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

SARS-CoV-2-IN-1

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products